Division of H. Lundbeck AS
Latest From Lundbeck Inc.
Government is pursuing behavior it once would have taken a pass on, former DOJ attorney notes; pharma companies have inked 16 settlements in past year.
Otsuka’s Avanir hit by failed second trial in Phase III program with candidate for agitation associated with Alzheimer’s, prompting a re-think of development plans and potentially helping rivals in a high-need indication.
The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Neurology, Nervous System
- Ovation Pharmaceuticals Inc.
- North America
- Parent & Subsidiaries
- H. Lundbeck AS
- Senior Management
- Doug Carlson, Sr. Dir., Corp. BD & Strategy
- Contact Info
Phone: (800) 455-1141
4 Parkway N.
Deerfield, IL 60015
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.